Format

Send to

Choose Destination
Am J Clin Dermatol. 2018 Apr;19(2):145-165. doi: 10.1007/s40257-017-0324-7.

Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis.

Author information

1
Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 4941492, Petah Tikva, Israel.
2
Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
3
Schneider Children's Medical Center, Petah Tikva, Israel.
4
Department of Dermatology, Beilinson Hospital, Rabin Medical Center, 4941492, Petah Tikva, Israel. daniel.mimouni@gmail.com.
5
Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel. daniel.mimouni@gmail.com.

Abstract

BACKGROUND:

Current systemic treatments for atopic dermatitis (AD) offer limited efficacy and are often restricted by safety concerns. Biologics may address the unmet need for improved AD therapeutics.

OBJECTIVE:

The aim of this study was to evaluate the efficacy and safety of biologic agents in AD.

METHODS:

A systematic review and meta-analysis of studies evaluating AD patients treated with biologics was performed. The primary outcome was the Eczema Area and Severity Index (EASI)-75 response, while secondary outcomes were SCOring Atopic Dermatitis (SCORAD)-75, EASI-50, SCORAD-50, Investigator Global Assessment 0/1 responses, change in responses from baseline, and adverse events.

RESULTS:

We included 13 randomized controlled trials (RCTs) and 10 observational studies evaluating nine biologics. High-quality evidence was available for dupilumab, nemolizumab and ustekinumab. Pooling five studies, at weeks 12-16 dupilumab 300 mg every week to every 2 weeks achieved EASI-75 responses of 55%, superior to placebo [relative risk (RR) 3.3, 95% confidence interval (CI) 2.9-3.6]. Nemolizumab had similar EASI-75 responses as placebo, but significantly improved pruritus. In online reports, lebrikizumab demonstrated superior EASI-50 responses versus placebo (RR 1.3, 95% CI 1.04-1.7), while tralokinumab had superior SCORAD-50 responses versus placebo, with borderline significance (RR 1.7, 95% CI 0.97-3.1). In two RCTs each, omalizumab and ustekinumab were comparable with placebo, while antithymic stromal lymphopoietin receptor, infliximab, and rituximab lacked adequate evidence of efficacy. All medications had a comparable safety profile to placebo.

LIMITATIONS:

Lack of RCTs and the use of variable outcome measures limited conclusions.

CONCLUSION:

Dupilumab is currently the only biologic with robust evidence of efficacy in AD. Nemolizumab, lebrikizumab, and tralokinumab show promise but further data are needed. Longer follow-up and larger studies will establish their safety profile.

PMID:
29098604
DOI:
10.1007/s40257-017-0324-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center